Little is known regarding the effect of antenatal COVID-19 on pregnancy outcomes. The purpose of this study is to determine of COVID-19 alters histopathology and gene expression of the placenta, as evidenced by analysis at time of delivery. The analysis will aim to identify whether resulting abnormal placental pathology or altered metabolism is associated with severity of symptoms (specifically pneumonia, or need for admission), gestational age at onset, and/or placenta efficiency. Histological and gene expression analysis of the placental post-delivery will determine if COVID-19 alters overall placental structure, vascularization, and/or the transcriptome.
Diagnostic Test: Positive for SARS-CoV-2 infection
Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
Inclusion Criteria:
1. COVID-19 infection during pregnancy, including at time of delivery
2. Age >=18 years
3. ≥13 6/7 weeks' GA
Exclusion Criteria:
1. Known major fetal chromosomal abnormality
2. Other major infection during pregnancy (specifically influenza A or B,
cytomegalovirus, toxoplasma, rubella, syphilis, HIV)
Prisma Health Upstate
Greenville, South Carolina, United States
Jessica Britt, PhD, Principal Investigator
Prisma Health-Upstate